FHTX

Foghorn Therapeutics Inc.

BS score 61.2MEDIUMPHASE1 · mkt cap $281.2M · rev ttm $30.9M

drug hypothesis

FHD-609 modulates Not stated in provided data (likely a synthetic lethal or protein degrader based on SMARCB1-loss context, but cannot confirm) to treat Advanced Synovial Sarcoma and Advanced SMARCB1-Loss Tumors.

moa:Not explicitly stated in provided clinical trial data

score breakdown

trial design70

base rate disconnect33

language red flags100

composite61.2

valuation analysis

market cap$281.2M

revenue ttm$30.9M

phasePHASE1

historical base rate5%

disconnect ratio1.1x

lead trialNCT07283094

meta

cik0001822462

first discovered2026-04-09

last updated2026-04-10

statusACTIVE

llm model—

extracted at2026-04-10

trial design

Phase 1, non-randomized, single-arm, open-label study enrolling 55 subjects with advanced synovial sarcoma or SMARCB1-loss tumors. Not placebo-controlled.

primary endpoint:Incidence of treatment-emergent adverse events (TEAEs)

claimed differentiation

Not provided in clinical trial data

language red flags

TRIAL TERMINATED - significant adverse signal requiring investigation
Primary endpoint is safety (TEAEs) rather than efficacy, typical of early Phase 1
No target or mechanism disclosed in trial registry data
No preclinical evidence summary provided
Indication is rare (synovial sarcoma), limiting commercial potential
SMARCB1-loss tumors represent heterogeneous patient population